Vexus Assessment and Natriuresis-guided Diuretic Therapy in Acute Heart Failure
NCT07558798
Cardiovascular Diseases, Diuretics
Lørenskog, Akershus, Norway
View Trial DetailsNCT Number: NCT07131228
In critically ill patients, appropriate fluid administration is one of the cornerstones of hemodynamic management, as both hypovolemia and fluid overload can negatively impact clinical outcomes.
For years, fluid responsiveness-defined as an increase in cardiac output following volume administration-has guided decision-making in the postoperative ICU. However, fluid responsiveness alone does not guarantee fluid tolerance, which refers to the venous system's ability to accommodate volume without developing venous congestion or adverse effects such as pulmonary edema, renal or hepatic dysfunction.
The tidal volume challenge (TVC)-which consists of a transient increase in tidal volume from 6 to 8 mL/kg-has been shown to predict fluid responsiveness by enhancing the hemodynamic interaction between the heart and lungs during the cardiac cycle, as measured through dynamic arterial indices such as pulse pressure variation (PPV) or stroke volume variation (SVV). However, these indices do not provide information about fluid tolerance or the state of venous congestion.
Doppler ultrasound of the portal vein, specifically the portal pulsatility index (which under normal conditions presents as a continuous waveform due to the damping effects of the hepatic parenchyma and venous compliance), has been proposed as a non-invasive marker of systemic venous congestion. Studies have shown that an increase in the portal pulsatility index following volume loading may indicate the development of venous congestion and, therefore, poor fluid tolerance.
Since the tidal volume challenge transiently increases intrathoracic pressure and allows dynamic evaluation of cardiovascular responses, we propose that this interaction be assessed not only through arterial dynamic indices (which assess responsiveness) but also through changes in venous flow patterns-specifically, variations in portal pulsatility-so that both fluid responsiveness and tolerance can be predicted with the same test.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must meet all of the following:
Age ≥ 18 years at the time of enrollment.
Receiving controlled mechanical ventilation with a baseline tidal volume of 6 mL/kg of predicted body weight.
Clinical indication for assessment of fluid responsiveness.
Adequate acoustic window for ultrasound visualization of the portal vein.
Exclusion criteria
Participants will be excluded if they have any of the following:
Liver cirrhosis.
Right heart failure, defined as any of the following on prior echocardiography:
Tricuspid annular plane systolic excursion (TAPSE) < 16 mm
S' wave < 10 cm/s
Right ventricular fractional area change < 35%
Left heart failure (left ventricular ejection fraction < 50%).
Intra-abdominal hypertension.
Atrial fibrillation or other significant cardiac arrhythmias.
Tricuspid regurgitation.
Poor echogenic window preventing adequate ultrasound assessment.
Presence of spontaneous breathing activity.
Time frame: Measured immediately before and after the tidal volume challenge (1 minute).
Time frame: Assessed during the first 48 hours post-challenge.
The correlation between the change in portal pulsatility index (PPI) during the tidal volume challenge and the occurrence of clinical signs of fluid intolerance in critically ill patients. Clinical signs include acute kidney injury (as defined by KDIGO criteria), pulmonary congestion r lung ultrasound), and other hemodynamic indicators of poor fluid tolerance (proBNP).
Contact information is provided by the study sponsor or research team.
Hospital Universitario de Gran Canaria Doctor Negrín
Other
Acronym: SERLU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07558798
Cardiovascular Diseases, Diuretics
Lørenskog, Akershus, Norway
View Trial DetailsNCT07438015
Cardiovascular Diseases, Hyperemia
Besançon, France
View Trial DetailsNCT07183397
Cardiac Anaesthesia, Cardiac and Aortic Surgery
View Trial DetailsNCT06251713
Acute Kidney Injury, Cardiac Surgery
Bron, France
View Trial Details